1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Atazanavir (Synonyms: BMS 232632; BMS-232632; BMS232632)

Cat. No.: HY-17367
Handling Instructions

Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor.

For research use only. We do not sell to patients.
Atazanavir Chemical Structure

Atazanavir Chemical Structure

CAS No. : 198904-31-3

Size Price Stock Quantity
10 mg $60 Backordered
50 mg $120 Backordered
100 mg $200 Backordered

* Please select Quantity before adding items.

Other Forms of Atazanavir:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation


Atazanavir(BMS-232632) is an highly potent HIV-1 protease inhibitor. IC50 value: Target: HIV-1 protease inhibitor Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor. It has a pharmacokinetic profile that supports once-daily dosing and has demonstrated a unique resistance profile and superior virologic potency compared with other antiretrovirals in vitro. In subjects with HIV, atazanavir (400 mg once daily) produced rapid and sustained improvements in viral load and CD4 counts in both antiretroviral-naive as well as previously treated patients when used in combination with dual nucleoside reverse transcriptase inhibitor (NRTI) treatment [1]. After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7 mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89 microg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38 microg/mLh). Despite the decrease of distribution volume (Vd(ss)), the terminal half-life (t(1/2)) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vd(ss). On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL [2]. Clinical indications: HIV-1 infection Toxicity: torsades de pointes

Clinical Trial
Sponsor Condition Start Date Phase
ViiV Healthcare HIV-1 infection 2010-04-30 Phase 4
National Institute of Allergy and Infectious Diseases HIV infection 2003-03-31 Phase 4
Bristol-Myers Squibb Co HIV-1 infection 2012-11-30 Phase 4
Bristol-Myers Squibb Co HIV-1 infection 2012-02-29 Phase 4
University of Colorado at Denver and Health Sciences Center 2006-09-30 Phase 4
University of British Columbia HIV infection 2011-07-31 Phase 4
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.4187 mL 7.0936 mL 14.1872 mL
5 mM 0.2837 mL 1.4187 mL 2.8374 mL
10 mM 0.1419 mL 0.7094 mL 1.4187 mL







Please store the product under the recommended conditions in the Certificate of Analysis.


Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: